A $25.02 million Artivion position now represents 9.35% of the firm’s 13F assets under management.
Yarger Wealth Strategies disclosed a new $25.02 million stake in Artivion, purchasing 634,223 shares at a quarterly average price. The position, valued at $23.23 million as of May 13, 2026, became the firm’s largest holding, comprising 9.35% of its $248.43 million in reportable 13F assets.
Prior to this filing, Yarger Wealth had no exposure to Artivion. The medtech stock, trading at $22.77 on May 15, 2026, has declined 21.4% over the past year, trailing the S&P 500 by 46.6 percentage points. The firm’s next largest holdings include TDVG, VONG, VYM, and HTAB.
Artivion specializes in medical devices and implantable human tissues, including surgical adhesives and vascular grafts. The move signals confidence in a sector that has underperformed broader markets.